Dapagliflozin is the first SGLT-2 inhibitor listed in China, DECLARE–TIMI 58 trial showed that on the basis of standard treatment, the combination of dapagliflozin can significantly reduce the incidence of cardiovascular death or hospitalization for heart failure in T2DM patients with confirmed atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors of ASCVD (10). Here, SLC5A2 is linked to atherosclerosis.